Literature DB >> 2838620

Radioreceptor assay for alpha-MSH using mouse B16 melanoma cells+.

W Siegrist1, M Oestreicher, S Stutz, J Girard, A N Eberle.   

Abstract

A radioreceptor assay for alpha-MSH is described which is based on cultured mouse B16 melanoma cells and bioactive monoiodinated [Nle4]-alpha-MSH tracer. The assay was used (1) to study the binding characteristics of alpha-MSH to B16 cells, (2) to determine the relative binding activity of MSH peptides, and (3) to measure MSH in tissue extracts. The association of alpha-MSH to B16 cells reached a stable plateau after 3 h at 15 degrees C. At 25 degrees or 37 degrees C, the binding was transient and at 0-1 degree C, the association was very slow. The hormone-receptor complex was relatively stable between 0 degrees and 15 degrees C whereas a 50% dissociation was reached after 90 min at 25 degrees C and after 35 min at 37 degrees C. The mean KD for alpha-MSH of four saturation experiments was 1.3 nM and the number of receptors 9570 per cell. 1,10-Phenanthroline had a stabilizing effect in the binding assay when used at a 0.3 mM concentration. From the MSH peptides tested in the binding assay, some showed similar potencies in three bioassays (tyrosinase, melanin and Anolis skin), whereas others displayed considerably lower bioassay values than expected from the binding data. This shows that binding and bioactivity can be dissociated in some of the MSH peptides. The biological activity of MSH from the neurointermediate lobe of the rat pituitary as measured by its binding to B16 cells corresponds fairly well with RIA results; in the anterior lobe, alpha-MSH values are overestimated because of the large amount of ACTH present.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838620     DOI: 10.3109/10799898809048996

Source DB:  PubMed          Journal:  J Recept Res        ISSN: 0197-5110


  8 in total

Review 1.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

2.  Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues.

Authors:  T Quinn; X Zhang; Y Miao
Journal:  G Ital Dermatol Venereol       Date:  2010-04       Impact factor: 2.011

3.  Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors.

Authors:  S D Sharma; J Jiang; M E Hadley; D L Bentley; V J Hruby
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

4.  Melanotropin receptors demonstrated in situ in human melanoma.

Authors:  J B Tatro; M Atkins; J W Mier; S Hardarson; H Wolfe; T Smith; M L Entwistle; S Reichlin
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  Molecular cloning, functional expression and pharmacological characterization of a mouse melanocortin receptor gene.

Authors:  F Desarnaud; O Labbe; D Eggerickx; G Vassart; M Parmentier
Journal:  Biochem J       Date:  1994-04-15       Impact factor: 3.857

6.  "Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system.

Authors:  Molly E Martin; M Sue O'Dorisio; Whitney M Leverich; Kyle C Kloepping; Susan A Walsh; Michael K Schultz
Journal:  Recent Results Cancer Res       Date:  2013

7.  Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination.

Authors:  M F Giblin; N Wang; T J Hoffman; S S Jurisson; T P Quinn
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

8.  A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma.

Authors:  D R Bard; C G Knight; D P Page-Thomas
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.